Advertisement
Indian
LIC IPO gets larger bids from anchor investors
Singapore’s GIC Pte and Norway’s sovereign wealth fund are among...
EV fire incidents will be probed; industry bound to grow beyond our imagination: Transport Secy
Recently, Road Transport and Highways Minister Nitin Gadkari, who...
Go Digit clocks Rs 5,000 cr premium in FY22 on strong growth in motor, health insurance
Further, the company settled over 6.79 lakh claims worth Rs 2,186...
LIC keen to retain some stake in IDBI Bank for bancassurance gains: Chairman
MR Kumar , chairman,, LIC “Strictly speaking, we are below the...
International
Still no clarity from UK to assess financial market access, says EU
With less than two months before Britain’s full access to the EU ends under post-Brexit transition arrangements on Dec. 31, London’s giant financial hub faces being largely cut off from its biggest customer.
Britain’s finance minister, Rishi Sunak, said on Monday he would not wait for Brussels to decide on UK access and would instead unilaterally allow EU financial firms to offer selected services to UK customers from January.
U.S. crosses 10 million COVID-19 cases as third wave of infections surges
More than 237,000 Americans have died of COVID-19 since the illness caused by the coronavirus first emerged in China late last year.
The daily average of reported new deaths in the United States account for one in every 11 deaths reported worldwide each day, according to a Reuters analysis.
The number of reported deaths nationwide climbed by more than 1,000 for a fifth consecutive day on Saturday, a trend last seen in mid-August, according to a Reuters tally.
Investors bet vaccine sparks revival in beaten down stocks
As the market hype around the U.S. election ebbs, investors are now preparing for good vaccine news, which they believe is a matter of when, not if.
“It’s going to be absolutely massive,” said Stuart Oakley, head of cash currency trading at Nomura in London. “If we get a vaccine, we’re going to see all that pent up demand coming out.”
Of the roughly 45 vaccines undergoing human trials, those from Pfizer and Moderna are seen as possibly winning regulatory approval this year, with AstraZeneca not far behind.
Investors are looking beyond an expected “excitement rally” and at longer-term beneficiaries and short-selling opportunities.
Pfizer’s Covid vaccine prevents 90% of infections in large study
“Today is a great day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive, said.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,”he said.
Briefs
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Events
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Articles
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Features
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Data
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Interviews
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Facts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.